FDA Skeptical Of Maintenance Claims For Centacor's Remicade In Pediatric Ulcerative Colitis

Agency accepts 8-week efficacy, but says long-term data is sparse for the tumor necrosis factor inhibitor, which goes before the Gastrointestinal Drugs Advisory Committee July 21.